Rockville-based Emergent BioSolutions Inc. , which makes the only vaccine licensed by the Food and Drug Administration to protect against anthrax infection, has received FDA approval for a new, shorter-dosing schedule.
The new, supplemental biologics license application, follows trials to determine if the company’s BioThrax vaccine would be effective with as few as three doses over six months.
{iframe}http://www.bizjournals.com/washington/news/2012/05/18/emergent-gets-fda-approval-for.html?ana=e_du_pap&s=article_du&ed=2012-05-18{/iframe}